文献速递白血病造血干细胞移植与细胞治疗

接受血液或骨髓移植治疗的急性髓系白血病幸存者长期疾病负担:BMT幸存者研究结果

Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
PubMed 文献 · J Clin Oncol · 2022-06-22

该多中心研究纳入1974至2014年间因急性髓系白血病接受血液或骨髓移植且年龄≥21岁的1369名2年幸存者及1310名同胞,发现幸存者严重/危及生命状况患病率为54.9%而同胞为28.5%(P<.001),幸存者严重/危及生命状况的比值比为3.8倍(95%CI 3.1至4.7),20年累积发生率为68%,慢性移植物抗宿主病与肺病、白内障和静脉血栓栓塞风险升高相关。

要点

  • 血液或骨髓移植幸存者严重/危及生命状况患病率为54.9%,同胞为28.5%(P<.001)。
  • 幸存者发生严重/危及生命状况的比值比为3.8倍(95%CI 3.1至4.7)。
  • 慢性移植物抗宿主病与肺病(HR 3.1)、白内障(HR 2.6)和静脉血栓栓塞(HR 2.3)风险升高相关。

核心结论

  • 与未受影响的对照组相比,血液或骨髓移植接受者的严重/危及生命状况负担显著更高,导致非复发相关死亡率随时间推移而增加。
  • 慢性移植物抗宿主病是血液或骨髓移植接受者发生严重/危及生命/致命状况的重要危险因素,提示需要密切监测以预见和管理疾病负担。

研究设计与样本

  • 多中心研究纳入1974至2014年间因急性髓系白血病接受血液或骨髓移植且年龄≥21岁的1369名2年幸存者及1310名同胞。
  • 使用不良事件通用术语标准识别严重/危及生命和致命的慢性健康状况,采用多变量回归分析比较幸存者与同胞之间的风险及健康状况,并识别血液或骨髓移植幸存者中健康状况的危险因素。

主要发现

  • 严重/危及生命状况的患病率在血液或骨髓移植幸存者中为54.9%,在同胞中为28.5%(P<.001),幸存者发生严重/危及生命状况的比值比为3.8倍(95%CI 3.1至4.7)。
  • 最常见的状况包括后续肿瘤、糖尿病、白内障、静脉血栓栓塞和关节置换。
  • 幸存者更可能报告总体健康状况差(OR 3.8;95%CI 2.8至5.1)、活动受限(OR 3.7;95%CI 3.0至4.5)和功能受损(OR 2.9;95%CI 2.3至3.6)。
  • 在血液或骨髓移植接受者中,严重/危及生命/致命状况的20年累积发生率为68%。
  • 慢性移植物抗宿主病病史与肺病风险升高相关(HR 3.1;95%CI 1.0至9.3),与白内障风险升高相关(HR 2.6;95%CI 1.4至3.8),与静脉血栓栓塞风险升高相关(HR 2.3;95%CI 1.3至4.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Blood or marrow transplantation (BMT) is an integral part of consolidation and/or salvage therapy for patients with acute myeloid leukemia (AML). With the growing population of AML survivors, there is a need to understand the quality of their survival. MATERIALS AND METHODS: This multisite study included 1,369 2-year survivors who underwent BMT for AML between 1974 and 2014 at age ≥ 21 years and 1,310 siblings. Using Common Terminology Criteria for Adverse Events, severe/life-threatening and fatal chronic health conditions were identified. Multivariable regression analysis was used to compare the risk of severe/life-threatening conditions and health status between survivors and siblings, and to identify risk factors for health conditions among BMT survivors. RESULTS: The prevalence of severe/life-threatening conditions was 54.9% in BMT survivors compared with 28.5% in siblings (P < .001), yielding 3.8-fold higher odds of severe/life-threatening conditions (95% CI, 3.1 to 4.7) among the BMT survivors. The most prevalent conditions included subsequent neoplasms, diabetes, cataracts, venous thromboembolism, and joint replacement. Survivors were more likely to report poor general health (odds ratio [OR], 3.8; 95% CI, 2.8 to 5.1), activity limitation (OR, 3.7; 95% CI, 3.0 to 4.5), and functional impairment (OR, 2.9; 95% CI, 2.3 to 3.6). Among BMT recipients, the 20-year cumulative incidence of severe/life-threatening/fatal conditions was 68%. History of chronic graft-versus-host disease was associated with a higher risk of pulmonary disease (hazard ratio [HR], 3.1; 95% CI, 1.0 to 9.3), cataract (HR, 2.6; 95% CI, 1.4 to 3.8), and venous thromboembolism (HR, 2.3; 95% CI, 1.3 to 4.7). Relapse-related mortality (RRM) plateaued at 30%, whereas non-RRM increased to 50% at 30 years. CONCLUSION: The burden of severe/life-threatening conditions is substantially higher in BMT recipients when compared with an unaffected comparison group, contributing to an increasing incidence of non-RRM over time. Chronic graft-versus-host disease was an important risk factor for severe/life-threatening/fatal conditions among BMT recipients, informing the need for close monitoring to anticipate and manage morbidity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Armenian SH, Chen Y, Hageman L, et al. Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study. J Clin Oncol. 2022. PMID: 35731989. doi:10.1200/JCO.21.02829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。